3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Myeloid
1
Lymphoid
1
Conditions
Precursor Cell Lymphoblastic Leukemia-Lymphoma
5
Myelodysplastic Syndromes
3
Leukemia
3
Immunoproliferative Disorders
3
Immune System Diseases
3
Lymphoma, Non-Hodgkin
2
Lymphoma
2
Leukemia, Myeloid, Acute
2
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
2
Leukemia, Lymphocytic, Chronic, B-Cell
2
Hodgkin Disease
2
Cytokine Release Syndrome
2
Breast Neoplasms
2
Triple Negative Breast Neoplasms
1
Stomach Neoplasms
1
Recurrence
1
Neurotoxicity Syndromes
1
Neoplasms, Plasma Cell
1
Neoplasm, Residual
1
Neoplasm Metastasis
1
Myeloproliferative Disorders
1
Myelodysplastic-Myeloproliferative Diseases
1
Multiple Myeloma
1
Lymphoproliferative Disorders
1
Lymphoma, B-Cell
1
Lymphohistiocytosis, Hemophagocytic
1
Lymphatic Diseases
1
Leukemia, Myelomonocytic, Chronic
1
Leukemia, Biphenotypic, Acute
1
Epstein-Barr Virus Infections
1
Interventions
Rituximab
7
Valganciclovir
5
Valacyclovir
3
Gemcitabine
3
Dexamethasone
3
Cisplatin
3
spartalizumab
2
pegaspargase
2
Radiotherapy, Intensity-Modulated
2
Methylprednisolone
2
Lenalidomide
2
Etoposide
2
Doxorubicin
2
Cell Count
2
Blood Specimen Collection
2
valomaciclovir
1
toripalimab
1
ruxolitinib
1
pembrolizumab
1
merphos
1
fludarabine
1
dehydroftorafur
1
avelumab
1
apatinib
1
Zidovudine
1
Watchful Waiting
1
Valproic Acid
1
Vaccines
1
Tenofovir
1
Tegafur
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Epstein-Barr Virus Infections
×
AP 1903 reagent
×
Clear all
NCT01494103
2025-07-11
DOTTI
Baylor College of Medicine
Phase 1
Active not recruiting
15 enrolled